Longitudinal community walking activity in Duchenne muscular dystrophy

Muscle and Nerve

Volumn 57, Issue 3, 2018, Pages 401-406

  Fowler, Eileen G ^a   Staudt, Loretta A ^a   Heberer, Kent R ^a   Sienko, Susan E ^b   Buckon, Cathleen E ^b   Bagley, Anita M ^c   Sussman, Michael D ^b   McDonald, Craig M ^c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SHRINERS HOSPITAL FOR CHILDREN   (United States)

^c SHRINERS HOSPITALS FOR CHILDREN NORTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

accelerometry; community walking; Duchenne muscular dystrophy; gait; natural history; physical activity

Indexed keywords

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; COMMUNITY; DUCHENNE MUSCULAR DYSTROPHY; HISTORY; HUMAN; LONGITUDINAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; VALIDITY; VELOCITY; WALKING; DISEASE EXACERBATION; GAIT; PATHOPHYSIOLOGY; PHYSIOLOGY; PRESCHOOL CHILD;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; GAIT; HUMANS; MALE; MUSCULAR DYSTROPHY, DUCHENNE; WALKING;

EID: 85026383513     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.25743     Document Type: Article

References (32)

1. Emery AE. Population frequencies of inherited neuromuscular diseases—a world survey. Neuromuscul Disord 1991;1:19–29.
2. Centers for Disease Control and Prevention (CDC). Prevalence of Duchenne/Becker muscular dystrophy among males aged 5–24 years—four states, 2007. MMWR Morb Mortal Wkly Rep 2009;58:1119–1122.
3. Henricson EK, Abresch RT, Cnaan A, Hu F, Duong T, Arrieta A, et al. The cooperative international neuromuscular research group Duchenne natural history study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures. Muscle Nerve 2013;48:55–67.
4. Balaban B, Matthews DJ, Clayton GH, Carry T. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect. Am J Phys Med Rehabil 2005;84:843–850.
5. Mendell JR, Moxley RT, Griggs RC, Brooke MH, Fenichel GM, Miller JP, et al. Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med 1989;320:1592–1597.
6. McDonald CM, Henricson EK, Han JJ, Abresch RT, Nicorici A, Atkinson L, et al. The 6-minute walk test in Duchenne/Becker muscular dystrophy: longitudinal observations. Muscle Nerve 2010;42:966–974.
7. Mazzone ES, Pane M, Sormani MP, Scalise R, Berardinelli A, Messina S, et al. 24 month longitudinal data in ambulant boys with Duchenne muscular dystrophy. PloS One 2013;8:e52512.
8. McDonald CM, Henricson EK, Abresch RT, Florence JM, Eagle M, Gappmaier E, et al. The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study. Muscle Nerve 2013;48:343–356.
9. Pane M, Mazzone ES, Sivo S, Sormani MP, Messina S, D Amico A, et al. Long term natural history data in ambulant boys with Duchenne muscular dystrophy: 36 month changes. PloS One 2014;9:e108205.
10. Pizzato TM, Baptista CR, Souza MA, Benedicto MM, Martinez EZ, Mattiello-Sverzut AC. Longitudinal assessment of grip strength using bulb dynamometer in Duchenne muscular dystrophy. Braz J Phys Ther 2014;18:245–251.
11. Brehm M-A, Kempen JC, van der Kooi AJ, de Groot IJ, van den Bergen JC, Verschuuren JJ, et al. Age-related longitudinal changes in metabolic energy expenditure during walking in boys with Duchenne muscular dystrophy. PloS One 2014;9:e115200.
12. Goemans NM, Tulinius M, van den Akker JT, Burm BE, Ekhart PF, Heuvelmans N, et al. Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med 2011;364:1513–1522.
13. van Deutekom JC, Janson AA, Ginjaar IB, Frankhuizen WS, Aartsma-Rus A, Bremmer-Bout M, et al. Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 2007;357:2677–2686.
14. Voit T, Topaloglu H, Straub V, Muntoni F, Deconinck N, Campion G, et al. Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study. Lancet Neurol 2014;13:987–996.
15. Mendell JR, Goemans N, Lowes LP, Alfano LN, Berry K, Shao J, et al. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann Neurol 2016;79:257–271.
16. Bushby K, Finkel R, Wong B, Barohn R, Campbell C, Comi GP, et al. Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve 2014;50:477–487.
17. McDonald CM, Widman LM, Walsh DD, Walsh SA, Abresch RT. Use of step activity monitoring for continuous physical activity assessment in boys with Duchenne muscular dystrophy. Arch Phys Med Rehabil 2005;86:802–808.
18. Telford RM, Telford RD, Cunningham RB, Cochrane T, Davey R, Waddington G. Longitudinal patterns of physical activity in children aged 8 to 12 years: the LOOK study. Int J Behav Nutr Phys Act 2013;10:81-92.
19. Tudor-Locke C, Washington TL, Hart TL. Expected values for steps/day in special populations. Prev Med 2009;49:3-11.
20. McDonald CM, Widman L, Abresch RT, Walsh SA, Walsh DD. Utility of a step activity monitor for the measurement of daily ambulatory activity in children. Arch Phys Med Rehabil 2005;86:793–801.
21. Downs J, Leonard H, Jacoby P, Brisco L, Baikie G, Hill K. Rett syndrome: establishing a novel outcome measure for walking activity in an era of clinical trials for rare disorders. Disabil Rehabil 2014;37:1992–1996.
22. Bjornson KF. Physical activity monitoring in children and youths. Pediatr Phys Ther 2005;17:37–45.
23. Song KM, Bjornson KF, Cappello T, Coleman K. Use of the StepWatch activity monitor for characterization of normal activity levels of children. J Pediatr Orthop 2006;26:245–249.
24. Bjornson KF, Zhou C, Stevenson R, Christakis D, Song K. Walking activity patterns in youth with cerebral palsy and youth developing typically. Disabil Rehabil 2014;36:1279–1284.
25. Tudor-Locke C, Bassett D Jr. How many steps/day are enough? Sports Med 2004;34:1–8.
26. Davidson ZE, Ryan MM, Kornberg AJ, Walker KZ, Truby H. Strong correlation between the 6-minute walk test and accelerometry functional outcomes in boys with Duchenne muscular dystrophy. J Child Neurol 2015;30:357–363.
27. Jeannet P-Y, Aminian K, Bloetzer C, Najafi B, Paraschiv-Ionescu A. Continuous monitoring and quantification of multiple parameters of daily physical activity in ambulatory Duchenne muscular dystrophy patients. Eur J Paediatr Neurol 2011;15:40–47.
28. Graser SV, Vincent WJ, Pangrazi RP. Step it up: activity intensity using pedometers. J Phys Educ Recreat Dance 2009;80:22–24.
29. Verbeke G, Molenberghs G. Linear mixed models for longitudinal data. New York: Springer-Verlag; 2000. Chapters 7,8.
30. Lythgo N, Wilson C, Galea M. Basic gait and symmetry measures for primary school-aged children and young adults. II: Walking at slow, free, and fast speed. Gait Posture 2011;33:29–35.
31. Shieh PB. Duchenne muscular dystrophy: clinical trials and emerging tribulations. Curr Opin Neurol 2015;28:542–546.
32. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010;9:77–93.